相关实验视频

Updated: May 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

在小分子JAK2抑制剂的近期进展和未来前景

Muhammad Yasir¹, Jongseon Choe², Mubashir Hassan³

¹Department of Pharmacology, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.

Future medicinal chemistry

|May 20, 2025

概括

简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径调节免疫力和细胞生长. 这一审查详细介绍了JAK2的细节.

科学领域:

分子生物学分子生物学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径对于免疫功能,造血和细胞增殖至关重要.
JAK/STAT信号的调节失调与血液恶性瘤,自身免疫疾病和慢性炎症状况有关.
JAK2是该途径的关键组成部分,使其成为一个重要的治疗点.

研究的目的:

提供JAK/STAT信号的全面审查,重点关注JAK2.
探索JAK/STAT路径的监管者,包括SOCS,PIAS和PTP.
检查JAK2抑制剂的治疗场景,包括已批准和正在研究的药物.

主要方法:

关于JAK/STAT信号的结构和功能方面的文献综述.
对涉及SOCS,PIAS和PTP的监管机制的分析.
探索JAK2抑制剂疗法,包括计算方法 (分子对接,机器学习) 和实验验证 (激酶试验).

主要成果:

详细概述JAK/STAT路径组件及其作用.
确定维护细胞平衡的关键调节剂.
评估当前和新兴的JAK2抑制剂,它们的疗效和安全性.

结论:

JAK/STAT信号传递对细胞过程至关重要,其失调驱动重大疾病.
JAK2抑制剂代表了对各种疾病的有前途的治疗策略.
结合计算和实验方法的综合方法可以促进新型JAK2向疗法的开发.

关键词:

抑制了JAK2的发生.小分子抑制剂 JAK2 的小分子抑制剂.激活和关闭JAK/STAT通路的情况.发现药物的发现.新兴的 JAK2 抑制剂

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...